Patients with chronic hypoparathyroidism (hypoPT) experience a significant burden from complications related to decreased serum calcium, increased phosphorus, and absent or deficient parathyroid hormone (PTH). Most importantly, patients with chronic hypoPT managed with conventional therapy of oral calcium and active vitamin D supplementation have adverse kidney outcomes of nephrolithiasis/kidney stones, nephrocalcinosis, and chronic kidney disease (CKD). The advent of evolving approaches to mitigate hypopPT-related kidney complications is a paradigm shift in the management of this rare and highly disabling condition. Led by experts in the field and with the participation of 2 patient advocates, this immersive live discussion will highlight the evolution of management approaches toward reducing kidney-related complications and improving quality of life for patients with chronic hypoPT. Followed by a Q&A session, this will be a great opportunity for the audience to get detailed and thought-provoking answers to their questions.
Professor of Medicine
University of California San Francisco
San Francisco, California, United States
Professor of Medicine
Chief, Division of Endocrinology and Metabolism
University of Virginia School of Medicine
Charlottesville, Virginia, United States
Executive Director
HypoPARAthyroidism Association
Aldie, Virginia, United States
Associate Director
HypoPARAthyroidism Association
Frisco, Texas, United States
7:00 PM–7:30 PM
Registration and Dinner
7:30 PM
Welcome and Introduction
Dolores Shoback, MD
7:40 PM
Then, Now, and the Future: Chronic Hypoparathyroidism-Related Kidney Complications
Dolores M. Shoback, MD; Patient Advocates Patty Keating and Michele Rayes, CPhT, CSPT
8:10 PM
Then, Now, and the Future: What Does it All Mean for Patients?
Suzanne Jan de Beur, MD; Patient Advocates Patty Keating and Michele Rayes, CPhT, CSPT
8:25 PM
Concluding Remarks
Dolores Shoback, MD
8:30 PM
Audience Q&A
Boston, Massachusetts 02210
The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved accreditation with commendation.
The Endocrine Society designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Upon completion of this activity, participants will:
Have increased knowledge regarding the:
- Patient burden of chronic hypoPT despite current treatment approaches
- Evolving approaches to mitigate hypopPT-related kidney complications based on the latest evidence
Have greater competence related to
- Implementing management approaches to improve quality of life for patients with chronic hypoPT on conventional treatment
The goal of this activity is for learners to be better able to contrast past, current, and future approaches to manage different types of patients with chronic hypoparathyroidism and mitigate chronic hypo-PT related complications and comorbidities.
This activity is intended for physicians with an interest in HYpoPT amongst endocrinologists, nephrologists, internal medicine specialists, pediatric oncologists and retina specialists.
As a provider of continuing medical education (CME) accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society's Special Programs Committee (SPC). The commercial supporter(s) of this activity have no influence over the planning of this CME activity.
Supported by an independent educational grant from Amolyt Pharma.